Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$16.68 - $23.66 $2.71 Million - $3.84 Million
162,471 Added 1108.71%
177,125 $2.95 Million
Q2 2023

Aug 10, 2023

BUY
$18.02 - $29.36 $264,065 - $430,241
14,654 New
14,654 $405,000
Q4 2022

Feb 13, 2023

SELL
$7.36 - $11.17 $138,139 - $209,649
-18,769 Reduced 17.24%
90,107 $983,000
Q3 2022

Nov 10, 2022

SELL
$7.86 - $11.71 $17,685 - $26,347
-2,250 Reduced 2.02%
108,876 $918,000
Q2 2022

Aug 19, 2022

BUY
$7.06 - $25.52 $784,549 - $2.84 Million
111,126 New
111,126 $879,000
Q1 2021

May 17, 2021

SELL
$19.02 - $31.15 $298,633 - $489,086
-15,701 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $290,311 - $394,566
15,701 New
15,701 $317,000
Q2 2019

Aug 14, 2019

SELL
$8.98 - $12.96 $270,468 - $390,342
-30,119 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$6.5 - $13.77 $103,473 - $219,204
15,919 Added 112.11%
30,119 $379,000
Q4 2018

Feb 14, 2019

BUY
$6.3 - $10.44 $89,460 - $148,248
14,200 New
14,200 $96,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.94B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.